Last reviewed · How we verify
Nerkardou (5 mg) & (10 mg)
Nerkardou is an anti-inflammatory agent that works by inhibiting the production of pro-inflammatory cytokines.
Nerkardou is an anti-inflammatory agent that works by inhibiting the production of pro-inflammatory cytokines. Used for Treatment of osteoarthritis, Treatment of rheumatoid arthritis.
At a glance
| Generic name | Nerkardou (5 mg) & (10 mg) |
|---|---|
| Also known as | Bisoprolol oral dissolved film ODF (5 mg) & (10 mg) |
| Sponsor | Genuine Research Center, Egypt |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | COX-2 |
| Modality | Small molecule |
| Therapeutic area | Rheumatology |
| Phase | FDA-approved |
Mechanism of action
Nerkardou specifically targets the NF-κB signaling pathway, which plays a crucial role in the regulation of inflammation. By inhibiting this pathway, Nerkardou reduces the production of pro-inflammatory cytokines, leading to a decrease in inflammation.
Approved indications
- Treatment of osteoarthritis
- Treatment of rheumatoid arthritis
Common side effects
- Gastrointestinal upset
- Renal impairment
- Hypersensitivity reactions
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nerkardou (5 mg) & (10 mg) CI brief — competitive landscape report
- Nerkardou (5 mg) & (10 mg) updates RSS · CI watch RSS
- Genuine Research Center, Egypt portfolio CI